SOURCE: Cardima, Inc.

February 07, 2007 09:00 ET

Cardima Showcases Next Generation Ablation System at the CardioRhythm 2007 Conference in Hong Kong

FREMONT, CA -- (MARKET WIRE) -- February 7, 2007 -- Cardima, Inc. (OTCBB: CRDM), developer of the REVELATION® Tx, REVELATION® T-Flex and REVELATION® Helix ablation microcatheters and INTELLITEMP® Energy Management Device, hosted a luncheon symposium at the CardioRhythm 2007 Conference which was held at the Hong Kong Convention and Exhibition Center on February 4th, 2007.

Cardima's luncheon symposium, entitled "New System and Techniques for Catheter-Based Treatment of Atrial Fibrillation," was held before an audience which included electrophysiology physicians from the Asia-Pacific nations, the European Union and North America.

Jaswinder Gill, MBBChir, MD, FRCP, Director of Pacing and Electrophysiology at Guy's and St. Thomas' Hospitals of the National Health Service, London, UK, described the first use of Cardima's next generation ablation system in the left atrium of a human heart. Cardima's ablation system is comprised of the INTELLITEMP® Energy Management Device and the REVELATION® T-Flex linear ablation catheter.

Dr. Gill is currently conducting a thirty patients trial using the Cardima ablation system. In the past two months, he has successfully isolated the pulmonary veins in eight patients suffering from atrial fibrillation. According to Dr. Gill, the system demonstrated a safety profile that confirmed prior animal studies conducted at the Stanford University School of Medicine by Sung Chun, MD, Director of Cardiac Pacing and Electrophysiology at Palo Alto Medical Foundation, California. Dr. Gill also indicated that he performed the catheter-based left atrial MAZE procedure in a shorter time and safer manner as compared to conventional radio frequency ablation methods.

"Cardima's multi-electrode linear ablation catheter requires less energy to create the lesions and it is faster than conventional devices, as the INTELLITEMP® device energizes multiple electrodes at the same time," said Dr. Gill.

Gabriel B. Vegh, Chief Executive Officer of Cardima, added, "I am pleased that the REVELATION® T-Flex and the INTELLITEMP® is as effective as was intended in the hands of Dr. Gill. His presentation in Hong Kong is an important step in introducing Cardima to the Chinese market."

About Cardima, Inc.

Since our incorporation in November 1992, we have developed, produced and sold a variety of micro-catheters designed for the diagnosis and treatment of the two most common forms of cardiac arrhythmias: atrial fibrillation (AF) and ventricular tachycardia (VT). Since 2001 our efforts have primarily focused on developing differentiated products that diagnose and treat AF, including our REVELATION® Tx micro-catheter for use in the Electrophysiology (EP) market, and our Surgical Ablation System (SAS) for use in the surgical market.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties are set forth in the Company's filings with the Securities & Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information